1-deoxynojirimycin has been researched along with Cardiovascular Diseases in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, SN; Hedrington, MS | 1 |
| Fuchigami, M; Goda, T; Imai, C; Mochizuki, K; Osonoi, T; Saito, M | 1 |
| Fuchigami, M; Goda, T; Hariya, N; Inoue, S; Mochizuki, K; Osonoi, T; Saito, M | 1 |
| Goda, T; Harazaki, T; Imai, C; Inoue, S; Mochizuki, K | 1 |
| Adelman, MH; Monte, SV; Paladino, JA; Schentag, JJ | 1 |
| Aerts, JM; Aten, J; Bietrix, FM; Bijl, N; Boot, RG; Dekker, N; Groen, AK; Groener, J; Langeveld, M; Lombardo, E; Ottenhoff, R; Overkleeft, HS; Serlie, M; van Eijk, M; van Roomen, C; Wennekes, T | 1 |
| Schnell, O; Standl, E | 1 |
| Higa, M; Masuzaki, H; Sata, M; Shimabukuro, M; Yamakawa, K | 1 |
3 review(s) available for 1-deoxynojirimycin and Cardiovascular Diseases
| Article | Year |
|---|---|
Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes.
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Metformin; Prediabetic State | 2019 |
Glycosphingolipids and insulin resistance.
Topics: 1-Deoxynojirimycin; Adamantane; Animals; Cardiovascular Diseases; Ceramides; Diabetes Mellitus, Type 2; Dioxanes; Disease Models, Animal; Fatty Acids; Fatty Liver; Gaucher Disease; Glucosyltransferases; Glycosphingolipids; Humans; Insulin Resistance; Metabolic Syndrome; Mice; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Pyrrolidines; Receptor, Insulin; Signal Transduction | 2011 |
Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation.
Topics: 1-Deoxynojirimycin; Acarbose; Cardiovascular Diseases; Diabetes Complications; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol | 2012 |
3 trial(s) available for 1-deoxynojirimycin and Cardiovascular Diseases
| Article | Year |
|---|---|
Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.
Topics: 1-Deoxynojirimycin; Adult; Aged; Asian People; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; E-Selectin; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incretins; Interleukin-8; Japan; Male; Middle Aged; Prospective Studies; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vascular Cell Adhesion Molecule-1 | 2014 |
Switching α-glucosidase inhibitors to miglitol reduced glucose fluctuations and circulating cardiovascular disease risk factors in type 2 diabetic Japanese patients.
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Asian People; Blood Glucose; Cardiovascular Diseases; Chemokine CCL2; Diabetes Mellitus, Type 2; Drug Therapy, Combination; E-Selectin; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin; Male; Middle Aged; Prospective Studies; Risk Factors; Time Factors | 2014 |
Miglitol, α-glycosidase inhibitor, reduces visceral fat accumulation and cardiovascular risk factors in subjects with the metabolic syndrome: a randomized comparable study.
Topics: 1-Deoxynojirimycin; Adult; alpha-Glucosidases; Cardiovascular Diseases; Female; Glycoside Hydrolase Inhibitors; Humans; Intra-Abdominal Fat; Male; Metabolic Syndrome; Middle Aged; Obesity; Risk Factors; Risk Reduction Behavior | 2013 |
2 other study(ies) available for 1-deoxynojirimycin and Cardiovascular Diseases
| Article | Year |
|---|---|
Treatment with DPP-4I Anagliptin or α-GI Miglitol Reduces IGT Development and the Expression of CVD Risk Factors in OLETF Rats.
Topics: 1-Deoxynojirimycin; Animals; Aorta; Blood Glucose; Cardiovascular Diseases; Cell Adhesion Molecules; Cytokines; Fasting; Hyperglycemia; Hypoglycemic Agents; Interleukin-1beta; Leukocytes; Male; Postprandial Period; Pyrimidines; Rats; Rats, Inbred OLETF; Risk Factors; S100 Proteins; Tumor Necrosis Factor-alpha | 2015 |
Glucose supply and insulin demand dynamics of antidiabetic agents.
Topics: 1-Deoxynojirimycin; Acarbose; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dietary Carbohydrates; Energy Intake; Follow-Up Studies; Gluconeogenesis; Glucose; Glycated Hemoglobin; Heart Diseases; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Intestinal Absorption; Liver; Metformin; Myocardial Infarction; Thiazolidinediones | 2010 |